newsfilter
← Latest News
Business Wire·

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

– CORE-VNS is the largest prospective, multinational observational study evaluating contemporary VNS Therapy devices in people with Drug-Resistant Epilepsy – Demonstrated 76% median reduction in seizure frequency and a